Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Chronic Coronary Syndrome (CCS)

Published: 03 October 2022

  • Views:

    Views Icon 23184
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 1 | Session 1 of 1
    Unmet Needs in CCS
    Marc P Bonaca, Philippe Gabriel Steg, Deepak L Bhatt
    Up Next
  • episode_image
    Part 5 | Session 1 Q&A and Discussion
    Philippe Gabriel Steg, Marc P Bonaca, Eva Prescott, Deepak L Bhatt

Overview

This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.

 

The second broadcast in this series, focused on Chronic Coronary Syndrome (CCS). In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.

 

Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, FR) chairs the proceedings, and is joined by Dr Marc Bonaca (University of Colorado School of Medicine, US) and Dr Deepak Bhatt (Brigham and Women's Hospital, US) for a series of insightful presentations and discussions.

 

You can catch up on the first broadcast in this series, which focused on Acute Coronary Syndrome (ACS) here and the most recent broadcast on Balancing Risk Post-PCI here

 

This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

Following the completion of this programme, physicians will be in a position to:

  • Discuss the disease burden in both primary and secondary prevention patients with high-risk features
  • Identify clinical features that make CCS patients high risk
  • Choose an appropriate antiplatelet regimen for CCS patients based on relevant history and current risk profile
  • Recall the results of RCTs using potent P2Y12 inhibitors in CCS patients with a prior MI and in patients with existing diabetes, with/without MI

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses and any other allied HCPs

More from this programme

Part 1

Unmet Needs in CCS

In this first part, Dr Marc Bonaca discusses the current unmet needs in Chronic Coronary Syndrome.

Part 2

Risk Mitigation in High and Very High-Risk Patients: What Does the Data Say?

Prof Philippe Gabriel Steg looks at the data behind risk mitigation in high and very high-risk patients.

Part 3

Prevention in Diabetes

Dr Deepak Bhatt discusses primary and secondary prevention in patients with type 2 diabetes.

Part 4

Long-term Management of CCS

Dr Marc Bonaca discusses how to apply the evidence to practice looking at the long-term management of CCS.

Part 5

Q&A and Discussion

In this final chapter, Prof Philippe Gabriel Steg addresses questions received by the audience to our panel.

Faculty Biographies

Marc P Bonaca

Marc P Bonaca

Director of Vascular Research and an Associate Professor of Medicine

Dr Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health which is an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. CPC is a core resource of the University of Colorado research and community outreach infrastructure.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. Following his medical residency training, he served as a Cardiology Fellow at Brigham and Women’s Hospital and subsequently completed a…

View full profile
Philippe Gabriel Steg

Philippe Gabriel Steg

Interventional Cardiologist

Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France. 

Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.

Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…

View full profile
Deepak L Bhatt

Deepak L Bhatt

Executive Director of Interventional Cardiovascular Programs

Dr Deepak Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.

Dr Bhatt has more than 1,600 publications and has been listed by the Web of Science as a Highly Cited Researcher.

He is Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.

View full profile